Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status
- PMID: 20021291
- DOI: 10.1517/14740330903426151
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status
Abstract
Importance of the field: Although genetic polymorphisms in the gene encoding human thiopurine methyltransferase (TPMT) are known to have a marked effect on mercaptopurine metabolism and toxicity, there are many patients with wild-type TPMT who develop toxicity. Furthermore, when mercaptopurine dosages are adjusted in patients who are heterozygous at the TPMT locus, there are still some patients who develop toxicity for reasons that are not fully understood. Therefore, we recently studied the effects of a common polymorphism in another gene encoding an enzyme involved in mercaptopurine metabolism (SNP rs1127354 in inosine-triphospate-pyrophosphatase, ITPA), showing that genetic polymorphism of ITPA is a significant determinant of mercaptopurine metabolism and of febrile neutropenia following combination chemotherapy of acute lymphoblastic leukemia (ALL) in which mercaptopurine doses are individualized based on TPMT genotype.
Area covered in this review: In this review, we summarize the knowledge available about the effect and clinical relevance of TPMT and ITPA on mercaptopurine pharmacogenomics, with a particular focus on the use of this medication in pediatric patients with ALL.
What the reader will gain: Reader will gain insights into: i) the effects of pharmacogenomic traits on mercaptopurine toxicity and efficacy for the treatment of ALL and ii) individualization strategies that can be used to mitigate toxicity without compromising efficacy in pediatric patients with ALL.
Take home message: Mercaptopurine dose can be adjusted on the basis of TPMT genotype to mitigate toxicity in pediatric patients with ALL. As treatment is individualized in this way for the most relevant genetic determinant of drug response (i.e., for mercaptopurine, TPMT), the importance of other genetic polymorphisms emerges (e.g., ITPA).
Similar articles
-
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.Clin Pharmacol Ther. 2009 Feb;85(2):164-72. doi: 10.1038/clpt.2008.154. Epub 2008 Aug 6. Clin Pharmacol Ther. 2009. PMID: 18685564 Free PMC article.
-
Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.J Pediatr Hematol Oncol. 2020 Mar;42(2):e94-e97. doi: 10.1097/MPH.0000000000001707. J Pediatr Hematol Oncol. 2020. PMID: 31895215
-
Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.J Clin Pharm Ther. 2012 Apr;37(2):237-41. doi: 10.1111/j.1365-2710.2011.01272.x. Epub 2011 May 5. J Clin Pharm Ther. 2012. PMID: 21545474
-
Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.Pharmacogenomics. 2009 Aug;10(8):1309-22. doi: 10.2217/pgs.09.78. Pharmacogenomics. 2009. PMID: 19663675 Review.
-
The increasing complexity of mercaptopurine pharmacogenomics.Clin Pharmacol Ther. 2009 Feb;85(2):139-41. doi: 10.1038/clpt.2008.219. Clin Pharmacol Ther. 2009. PMID: 19151640 Review.
Cited by
-
ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics.Mutat Res. 2013 Oct-Dec;753(2):131-146. doi: 10.1016/j.mrrev.2013.08.001. Epub 2013 Aug 19. Mutat Res. 2013. PMID: 23969025 Free PMC article. Review.
-
ITPA:c.94C>A and NUDT15:c.415C>T Polymorphisms and Their Relation to Mercaptopurine-Related Myelotoxicity in Childhood Leukemia in Thailand.Appl Clin Genet. 2021 Jul 28;14:341-351. doi: 10.2147/TACG.S318912. eCollection 2021. Appl Clin Genet. 2021. PMID: 34349542 Free PMC article.
-
Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.J Gastroenterol. 2018 Feb;53(2):172-180. doi: 10.1007/s00535-017-1416-0. Epub 2017 Nov 30. J Gastroenterol. 2018. PMID: 29192347 Free PMC article. Review.
-
Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Clin Pharmacokinet. 2016 Mar;55(3):257-74. doi: 10.1007/s40262-015-0316-9. Clin Pharmacokinet. 2016. PMID: 26255287 Review.
-
A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.Mol Diagn Ther. 2016 Oct;20(5):493-9. doi: 10.1007/s40291-016-0217-0. Mol Diagn Ther. 2016. PMID: 27307154 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous